5AM Partners VII, LLC (DIEKMAN JOHN D, PARMAR KUSH) sold $140K of SKYE (indirect holdings)
5AM Partners VII, LLC sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which can be interpreted as a negative signal, but the amount is small.
Market read
Primary source insider sale; modest relevance for traders monitoring SKYE.
What to watch
Potential upcoming clinical data releases or financing events not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; investors monitor them for signals.
Ticker impact
5AM Partners VII sold 375,840 shares of Skye Bioscience for $140,313, reducing its stake to 7,850,155 shares.
Modest downward pressure in the near term.
Sale size is modest relative to market cap, but insider disposition can influence sentiment.
Market effects
Minimal impact on biotech sector; typical insider sale activity.
No significant regional effect.
Limited to investors tracking SKYE.
Counterpoint
The sale could be unrelated to fundamentals; may present a buying opportunity if the market overreacts.
Key entities
- CompanySkye Bioscience, Inc.
Biotech firm listed on NASDAQ under ticker SKYE.
- Insider5AM Partners VII, LLC
Investment firm holding a 10% stake in SKYE.